Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Faricimab
Treatment for Macular Degeneration
Typical Dosage: 6 mg intravitreal injection monthly for 4 doses, then extended up to every 16 weeks
Effectiveness
90%
Safety Score
45%
Clinical Trials
26
Participants
10K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
45
DangerousModerateSafe
Treatment Details
Dosage Range
6 mg intravitreal injection monthly for 4 doses, then extended up to every 16 weeks
Time to Effect
1-2 weeks
Treatment Duration
lifetime
Evidence Quality
HIGHConfidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$10,000
Monitoring:$700
Side Effect Mgmt:$300
Total Annual:$11,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODICER
$85,000/QALY
QALYs Gained
0.85
Outcome-Based Costs
Cost per Responder
$11,827.96
Comparison vs Aflibercept
Cost Difference
$-2,000/year
Less expensive
QALY Difference
+0.05 QALYs
Better outcomes
Dominance
DOMINATESBetter + cheaper
Faricimab Outcomes
for Macular Degeneration
Efficacy Outcomes
Overall Effectiveness
+90%
Response Rate
+93%
Common Side Effects
Conjunctival hemorrhage
+15%
Eye pain
+8%
Vitreous floaters
+7%
Increased intraocular pressure
+3%
Endophthalmitis
+0.05%
Retinal detachment
+0.05%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
11 active trials recruiting for Faricimab in Macular Degeneration
Evaluate the Efficacy of Faricimab in Patients With Neovascular Age-related Macular Degeneration
NCT07367282NOT YET RECRUITINGPHASE4
64 participants
INTERVENTIONAL
Seoul, South Korea
Started: Apr 1, 2026
Efficacy of Faricimab in Patients With Subretinal Hyper-reflective Material
NCT07403825NOT YET RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Started: Apr 1, 2026
Multicenter Real-life Observational Study Switched Aflibercept or Ranibizumab to Faricimab in Patients With AMD.
NCT06271330RECRUITING
100 participants
OBSERVATIONAL
Nantes, France
Started: Apr 1, 2024
Faricimab Quarterly Maintenance for Neovascular Age Related Macular Degeneration
NCT06742307RECRUITINGPHASE4
40 participants
INTERVENTIONAL
Hong Kong, Hong Kong
Started: Aug 21, 2025
A Real-World Study to Gain Clinical Insights Into Faricimab (FaReal Study)
NCT06680817RECRUITING
850 participants
OBSERVATIONAL
Graz, Austria +58 more
Started: Feb 5, 2025
Identification of Molecular Signals in Vitreous Humor Associated With Suboptimal Response to Vascular Endothelial Growth Factor (VEGF) Inhibition in Neovascular Age-related Macular Degeneration (nAMD) Within a Clinical Trial Setting
NCT07249216RECRUITINGNA
117 participants
INTERVENTIONAL
Singapore, Singapore
Started: Jul 18, 2025
A Study to Determine the Efficacy, Safety, and Durability of Faricimab in Participants With Neovascular Age-Related Macular Degeneration
NCT06795048ACTIVE NOT RECRUITINGPHASE4
274 participants
INTERVENTIONAL
Santa Ana, United States +66 more
Started: Mar 14, 2025
Therapeutic Prospects of Faricimab Injection for Patients Affected by Neovascular Age-Related Macular Degeneration
NCT07088445NOT YET RECRUITING
35 participants
OBSERVATIONAL
Started: Sep 1, 2025
Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals
NCT06875245RECRUITINGPHASE4
100 participants
INTERVENTIONAL
Prague, Czechia
Started: Mar 31, 2023
Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Related Macular Degeneration (The Farseeing Study)
NCT06439576ACTIVE NOT RECRUITING
1K participants
OBSERVATIONAL
Shantou, China +40 more
Started: May 9, 2024
Efficacy and Durability of a Personalized Treat-and-extend Regimen of Faricimab for Treatment-naive Polypoidal Choroidal Vasculopathy
NCT07461441RECRUITINGPHASE3
50 participants
INTERVENTIONAL
Daegu, South Korea
Started: Mar 1, 2026
Completed Clinical Trials
8 completed trials for Faricimab in Macular Degeneration
Intravitreal Faricimab in Patients With Refractory Macular Edema
NCT07093385COMPLETEDPHASE2
43 participants
INTERVENTIONAL
Baghdad, Iraq
Started: Sep 10, 2024
Switching to Faricimab in Neovascular Age-related Macular Degeneration Resistant to Both Aflibercept and Ranibizumab
NCT06231121COMPLETED
13 participants
OBSERVATIONAL
Glostrup Municipality, Denmark
Started: Dec 1, 2023
Single Injection of Faricimab for nAMD With Persisting Fluid Despite Frequent Aflibercept Treatments
NCT06124677COMPLETED
46 participants
OBSERVATIONAL
Glostrup Municipality, Denmark
Started: Nov 1, 2023
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (TENAYA)
NCT03823287COMPLETEDPHASE3
671 participants
INTERVENTIONAL
Phoenix, United States +160 more
Started: Feb 19, 2019
A Study to Evaluate the Efficacy and Safety of Faricimab in Participants With Neovascular Age-Related Macular Degeneration (LUCERNE)
NCT03823300COMPLETEDPHASE3
658 participants
INTERVENTIONAL
Phoenix, United States +136 more
Started: Mar 11, 2019
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
NCT03038880COMPLETEDPHASE2
76 participants
INTERVENTIONAL
Phoenix, United States +24 more
Started: Jan 27, 2017
A Study in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema to Evaluate the Safety of the Faricimab Prefilled Syringe
NCT05569148COMPLETEDPHASE3
35 participants
INTERVENTIONAL
Mesa, United States +2 more
Started: Oct 17, 2022
A Phase 1b Study to Assess the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of Intravitreal OLN324
NCT07484074COMPLETEDPHASE1
164 participants
INTERVENTIONAL
Phoenix, United States +29 more
Started: Feb 12, 2025
Showing 20 of 33 total trials